Plasma proteomics profiling identifies predictive biomarkers for immunotherapy response in small-cell lung cancer [0.03%]
血浆蛋白质组分析可识别小细胞肺癌免疫治疗反应的预测生物标志物
Guang-Ling Jie,Jia-Xin Zhong,Jing-Ze Wang et al.
Guang-Ling Jie et al.
Introduction: Immune checkpoint inhibitors have improved clinical outcomes for small-cell lung cancer (SCLC), but patient responses vary widely, and predictive biomarkers remain inadequate. ...
Delivering equitable access to prehabilitation services to optimise outcomes for patients with lung cancer - Best practice recommendations from a UK roundtable event [0.03%]
英国圆桌会议最佳实践建议：向肺癌患者提供公平的康复服务以优化患者预后
William Ricketts,Catherine Sandsund,Zoe Merchant et al.
William Ricketts et al.
Introduction: Prehabilitation in patients with lung cancer has historically been focused on those undergoing surgical resection. However, its benefits could be applicable to those undergoing all forms of treatment both in...
Systematic review and network meta-analysis: evaluation of systemic therapies for platinum refractory or resistant small cell lung cancer [0.03%]
系统评价和网络meta分析：铂类药物难治或耐药的小细胞肺癌的全身治疗评估
Rahul K Desai,Elena J Zhou,Kelvin K W Chan
Rahul K Desai
Background: Platinum-refractory/resistant (r/r) small cell lung cancer (SCLC) is associated with poor prognosis and limited treatment options. While chemotherapy has been the standard, recent randomized controlled trials ...
Recommendations for radiotherapy in patients with lung cancer and interstitial lung disease: A Delphi consensus process of the Italian association of radiotherapy and clinical oncology (AIRO) [0.03%]
意大利放射治疗和临床肿瘤学会(AIRO)关于肺癌间质性肺病患者放射治疗的共识意见
Paolo Borghetti,Rolando D&#x;Angelillo,Giorgio Facheris et al.
Paolo Borghetti et al.
Aim: Interstitial lung diseases (ILD) are a group of disorders affecting the lung parenchyma. ILD patients have a higher risk of lung cancer and worse prognosis, with increased susceptibility to radiotherapy (RT)-related ...
Clinical characteristics and outcomes in participants with screen-detected clinical stage I lung cancer in the Yorkshire lung screening trial: A comparison of surgery versus stereotactic ablative radiotherapy [0.03%]
一项针对肺部癌症筛查计划中临床分期I期肺癌参与者的临床特征和结局的分析：手术与立体定向消融放射治疗的比较——约克郡肺筛查试验报告
Hannah R Bailey,Hui Zhen Tam,Daniel Vulkan et al.
Hannah R Bailey et al.
Background: Lung cancer screening with low-dose computed tomography (LDCT) saves lives by detecting early-stage curable cancer and estimates of overdiagnosis in the previous randomised studies were generally low. Screenin...
The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study [0.03%]
体重指数对伴发转移的非小细胞肺癌患者肿瘤治疗电场疗法的影响：来自III期LUNAR研究的事后和模拟分析
Christian Rolfo,David E Gerber,Rupesh Kotecha et al.
Christian Rolfo et al.
Introduction: In the phase III LUNAR study, overall survival (OS) with PD-(L)1 inhibitor or docetaxel was improved by adding Tumor Treating Fields (TTFields) therapy in patients with metastatic non-small cell lung cancer ...
Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinib [0.03%]
EGFR突变阳性晚期肺腺癌一线使用奥希替尼的失败模式、局部治疗的影响以及长期应答者的特征分析
Allen C C Chen,Florence S T Mok,Wesley K Y Wong et al.
Allen C C Chen et al.
Introduction: Recent randomized trials demonstrate that intensified therapy improves progression-free survival (PFS) and overall survival (OS)compared to osimertinib monotherapy in advancedEGFRmutant non-small cell lung c...
Overall survival in patients with non-small cell lung cancer and leptomeningeal metastases: Data from the Dutch cancer Registry [0.03%]
荷兰癌症登记处非小细胞肺癌伴脑膜转移患者的总生存期数据
Jarno W J Huijs,Francesca R Ogliari,Ronald A M Damhuis et al.
Jarno W J Huijs et al.
Background: Leptomeningeal metastases (LM) at initial diagnosis are a rare manifestation in patients with non-small cell lung cancer (NSCLC), historically associated with poor survival and limited treatment options. With ...
Patient preferences for EGFR mutation-targeted therapies in non-small cell lung cancer, with a focus on Exon 20 insertions [0.03%]
非小细胞肺癌患者EGFR突变靶向治疗的偏好分析——聚焦 exon20插入突变患者
Jaein Seo,Eileen Curran,Jennifer A Whitty et al.
Jaein Seo et al.
Introduction: This study investigated treatment preferences of patients with non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) mutations, e.g., exon 20 insertion (ex20ins), and assessed the tr...
Pattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation [0.03%]
KRAS或EFGR突变型肺腺癌脑转移的模式及其与生存期的关系
Martin Faehling,Sabine Fallscheer,Julia Schmiederer et al.
Martin Faehling et al.
Background: NSCLC with mutations of the KRAS or EGFR gene is associated with a high risk of brain metastases (BRA). There are few data on the prevalence and pattern of BRA and on survival in unselected KRAS or EGFR patien...